Literature DB >> 25914472

Adjuvant transarterial chemoembolization after curative resection of hepatocellular carcinoma: propensity score analysis.

Jing-Hang Jiang1, Zhe Guo1, Hao-Feng Lu1, Xiao-Bo Wang1, Hao-Jie Yang1, Fu-Quan Yang1, Si-Yang Bao1, Jian-Hong Zhong1, Le-Qun Li1, Ri-Rong Yang1, Bang-De Xiang1.   

Abstract

AIM: To compare survival and recurrence in hepatocellular carcinoma (HCC) patients who did or did not receive adjuvant transarterial chemoembolization (TACE).
METHODS: A consecutive sample of 229 patients who underwent curative resection between March 2007 and March 2010 in our hospital was included. Of these 229 patients, 91 (39.7%) underwent curative resection followed by adjuvant TACE and 138 (60.3%) underwent curative resection alone. In order to minimize confounds due to baseline differences between the two patient groups, comparisons were conducted between propensity score-matched patients. Survival data and recurrence rates were compared using the Kaplan-Meier method. Independent predictors of overall survival and recurrence were identified using Cox proportional hazard regression.
RESULTS: Among 61 pairs of propensity score-matched patients, the 1-, 2-, and 3-year overall survival rates were 95.1%, 86.7%, and 76.4% in the TACE group and 86.9%, 78.5%, and 73.2% in the control group, respectively. At the same time, the TACE and control groups also showed similar recurrence rates at 1 year (13.4% vs 24.8%), 2 years (30.6% vs 32.1%), and 3 years (40.1% vs 34.0%). Multivariate Cox regression identified serum alpha-fetoprotein level ≥ 400 ng/mL and tumor size > 5 cm as independent risk factors of mortality (P < 0.05).
CONCLUSION: As postoperative adjuvant TACE does not improve overall survival or reduce recurrence in HCC patients, further study is needed to clarify its clinical benefit.

Entities:  

Keywords:  Curative resection; Hepatocellular carcinoma; Overall survival; Recurrence; Transarterial chemoembolization

Mesh:

Substances:

Year:  2015        PMID: 25914472      PMCID: PMC4402310          DOI: 10.3748/wjg.v21.i15.4627

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  34 in total

1.  Elevated serum alpha fetoprotein levels promote pathological progression of hepatocellular carcinoma.

Authors:  Peng Li; Shan-Shan Wang; Hui Liu; Ning Li; Michael A McNutt; Gang Li; Hui-Guo Ding
Journal:  World J Gastroenterol       Date:  2011-11-07       Impact factor: 5.742

2.  Adjuvant hepatic arterial infusional chemotherapy with 5-fluorouracil and cisplatin after curative resection of hepatocellular carcinoma.

Authors:  Do Young Kim; Sang Hoon Ahn; Seung Up Kim; Sae Byeol Choi; Kwang-Hun Lee; Mi Sook Park; Jun Yong Park; Do Yun Lee; Kwang-Hyub Han; Kyung Sik Kim
Journal:  Oncology       Date:  2011-11-08       Impact factor: 2.935

3.  Adjuvant hepatic arterial infusion chemotherapy after hepatic resection of hepatocellular carcinoma with macroscopic vascular invasion.

Authors:  Hidetoshi Nitta; Toru Beppu; Katsunori Imai; Hiromitsu Hayashi; Akira Chikamoto; Hideo Baba
Journal:  World J Surg       Date:  2013-05       Impact factor: 3.352

4.  Comparison of surgical resection and transarterial chemoembolization for hepatocellular carcinoma beyond the Milan criteria: a propensity score analysis.

Authors:  Chia-Yang Hsu; Cheng-Yuan Hsia; Yi-Hsiang Huang; Chien-Wei Su; Han-Chieh Lin; Jih-Tung Pai; Che-Chuan Loong; Yi-You Chiou; Rheun-Chuan Lee; Fa-Yauh Lee; Teh-Ia Huo; Shou-Dong Lee
Journal:  Ann Surg Oncol       Date:  2011-09-13       Impact factor: 5.344

5.  Resection of hepatocellular carcinoma with macroscopic vascular invasion.

Authors:  Sasan Roayaie; Ghalib Jibara; Bachir Taouli; Myron Schwartz
Journal:  Ann Surg Oncol       Date:  2013-07-25       Impact factor: 5.344

6.  Recurrence of hepatocellular carcinoma in noncirrhotic liver after hepatectomy.

Authors:  Laurence Chiche; B Menahem; C Bazille; V Bouvier; L Plard; V Saguet; A Alves; E Salame
Journal:  World J Surg       Date:  2013-10       Impact factor: 3.352

7.  A randomized controlled trial of hepatectomy with adjuvant transcatheter arterial chemoembolization versus hepatectomy alone for Stage III A hepatocellular carcinoma.

Authors:  Chong Zhong; Rong-ping Guo; Jin-qing Li; Ming Shi; Wei Wei; Min-shan Chen; Ya-qi Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2009-05-01       Impact factor: 4.553

8.  Transcatheter arterial chemoembolization vs. chemoinfusion for unresectable hepatocellular carcinoma in patients with major portal vein thrombosis.

Authors:  J H Kim; H-K Yoon; S Y Kim; K M Kim; G-Y Ko; D I Gwon; K-B Sung
Journal:  Aliment Pharmacol Ther       Date:  2009-04-08       Impact factor: 8.171

9.  Tumor size of hepatocellular carcinoma in noncirrhotic liver: a controversial predictive factor for outcome after resection.

Authors:  S Truant; E Boleslawski; A Duhamel; A-F Bouras; A Louvet; C Febvay; E Leteurtre; G Huet; P Zerbib; S Dharancy; M Hebbar; F-R Pruvot
Journal:  Eur J Surg Oncol       Date:  2012-08-03       Impact factor: 4.424

10.  A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma.

Authors:  Chung Mau Lo; Chi Leung Liu; See Ching Chan; Chi Ming Lam; Ronnie T P Poon; Irene O L Ng; Sheung Tat Fan; John Wong
Journal:  Ann Surg       Date:  2007-06       Impact factor: 12.969

View more
  20 in total

1.  Efficacy of combined adjuvant transarterial chemoembolization and antiviral therapy in patients with HBV-related hepatocellular carcinoma after surgery.

Authors:  Song-Lin Ma; Yang Lv; Jing-Hang Jiang
Journal:  Tumour Biol       Date:  2015-09-05

2.  Blood neutrophil-lymphocyte ratio predicts survival after hepatectomy for hepatocellular carcinoma: A propensity score-based analysis.

Authors:  Hao-Jie Yang; Zhe Guo; Yu-Ting Yang; Jing-Hang Jiang; Ya-Peng Qi; Ji-Jia Li; Le-Qun Li; Bang-De Xiang
Journal:  World J Gastroenterol       Date:  2016-06-07       Impact factor: 5.742

3.  Tumor Size Affects Efficacy of Adjuvant Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma and Microvascular Invasion.

Authors:  Shuang Liu; Hui Li; Lei Guo; Bo Zhang; Binghai Zhou; Wentao Zhang; Jian Zhou; Jia Fan; Qinghai Ye
Journal:  Oncologist       Date:  2018-12-14

4.  Adjuvant Transcatheter Arterial Infusion Therapy for Hepatocellular Carcinoma: Not Yet for Everybody.

Authors:  Kevin P Labadie; Jonathan G Sham
Journal:  Ann Surg Oncol       Date:  2020-06-04       Impact factor: 5.344

5.  Feasibility of combining adjuvant transarterial chemoembolization with nucleos(t)ide analog therapy for patients with HBV-associated hepatocellular carcinoma after hepatectomy.

Authors:  Wen-Feng Gong; Jian-Hong Zhong; Bang-DE Xiang; LE-Qun Li
Journal:  Mol Clin Oncol       Date:  2016-04-22

6.  Pattern of disease recurrence and its implications for postoperative surveillance after curative hepatectomy for hepatocellular carcinoma: experience from a single center.

Authors:  Kit-Fai Lee; Charing C N Chong; Anthony K W Fong; Andrew K Y Fung; Hon-Ting Lok; Yue-Sun Cheung; John Wong; Paul B S Lai
Journal:  Hepatobiliary Surg Nutr       Date:  2018-10       Impact factor: 7.293

7.  The efficacy and safety of postoperative adjuvant transarterial embolization and radiotherapy in hepatocellular carcinoma patients with portal vein tumor thrombus.

Authors:  Tao Bai; Jie Chen; Zhi-Bo Xie; Fei-Xiang Wu; Si-Da Wang; Jun-Jie Liu; Le-Qun Li
Journal:  Onco Targets Ther       Date:  2016-06-27       Impact factor: 4.147

8.  Optimizing stage of single large hepatocellular carcinoma: A study with subgroup analysis by tumor diameter.

Authors:  Jian-Hong Zhong; Ling-Hui Pan; Yan-Yan Wang; Alessandro Cucchetti; Tian Yang; Xue-Mei You; Liang Ma; Wen-Feng Gong; Bang-De Xiang; Ning-Fu Peng; Fei-Xiang Wu; Le-Qun Li
Journal:  Medicine (Baltimore)       Date:  2017-04       Impact factor: 1.889

9.  Prognostic nomogram for patients with hepatocellular carcinoma underwent adjuvant transarterial chemoembolization following curative resection.

Authors:  Chu-Yu Jing; Yi-Peng Fu; Su-Su Zheng; Yong Yi; Hu-Jia Shen; Jin-Long Huang; Xin Xu; Jia-Jia Lin; Jian Zhou; Jia Fan; Zheng-Gang Ren; Shuang-Jian Qiu; Bo-Heng Zhang
Journal:  Medicine (Baltimore)       Date:  2017-03       Impact factor: 1.889

10.  Preoperative transcatheter arterial chemotherapy may suppress oxidative stress in hepatocellular carcinoma cells and reduce the risk of short-term relapse.

Authors:  Hao Su; Guangzhi Zhu; Ketut Indra Djaja P; Yi Lin; Yizhen Gong; Xiaoguang Liu; Jiaquan Li; Zhiming Liu; Xiao Qin; Lequn Li; Tangwei Liu; Zili Lu; Minyi Wei; Lunan Yan; Cheryl Ann Winkler; Stephen J O'Brien; Jing Li; Kaiyin Xiao; Tao Peng
Journal:  Oncotarget       Date:  2017-05-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.